GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

A US retrospective analysis showed significant seasonal and temporal variation in eosinophilic esophagitis-related emergency department visits.

Physician researchers at Phoenix Children's have pioneered the use of the esophageal string test (EST), a minimally invasive ...

Researchers at the, Riverside, backed by a substantial NIH grant, are pioneering a study on the unique immune responses to ...

Autoimmune diseases are a pathophysiological state wherein immune responses are directed against, and damage, the body's own tissues (autoimmunity). Common examples of autoimmune disease include ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American ...